Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid:

Abstract: Background: The question of which colloid (albumin or synthetic colloids) used for plasma expansion following paracentesis or other complications requiring fluid loading in patients with cirrhosis remains controversial.

[1]  J. Vincent,et al.  Morbidity in hospitalized patients receiving human albumin: A meta-analysis of randomized, controlled trials* , 2004, Critical care medicine.

[2]  R. Moreau,et al.  The management of ascites in cirrhosis: Report on the consensus conference of the international Ascites club , 2003, Hepatology.

[3]  T W Evans,et al.  Review article: albumin as a drug—biological effects of albumin unrelated to oncotic pressure , 2002, Alimentary pharmacology & therapeutics.

[4]  D. Predescu,et al.  Transport of nitrated albumin across continuous vascular endothelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Mcguire,et al.  Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. , 2000, Health economics.

[6]  M. Navasa,et al.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. , 1999, The New England journal of medicine.

[7]  D. Roulot,et al.  Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis , 1998, European journal of gastroenterology & hepatology.

[8]  W. Jiménez,et al.  Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. , 1997, Gastroenterology.

[9]  W. Jiménez,et al.  Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. , 1996, Gastroenterology.

[10]  J. Schölmerich,et al.  Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.

[11]  M. R. Mölken,et al.  Statistical analysis of cost outcomes in a randomized controlled clinical trial. , 1994 .

[12]  R. Terg,et al.  Paracentesis with Dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. , 1992, Journal of hepatology.

[13]  S. Badalamenti,et al.  Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites , 1991, Hepatology.

[14]  J. Llach,et al.  Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. , 1990, Gastroenterology.

[15]  J. Llach,et al.  Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. , 1988, Gastroenterology.

[16]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[17]  G. Davis,et al.  Management of ascites in patients with end-stage liver disease. , 2004, Reviews in gastroenterological disorders.

[18]  J. Daurès,et al.  Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. , 2002, Annals of hepatology.

[19]  P. Pikkarainen.  [Treatment of ascites]. , 1993, Duodecim; laaketieteellinen aikakauskirja.

[20]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[21]  Ruddle Fh,et al.  Human gene mapping 3. Baltimore Conference (1975). Third International Workshop on Human Gene Mapping. Report of the committee on the genetic constitution of autosomes other than chromosomes 1, 2, and 6. , 1976, Cytogenetics and cell genetics.